Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cryo Cell International (CCEL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to 24.29%.

  • Cryo Cell International's EBITDA Margin rose 70600.0% to 24.29% in Q3 2025 from the same period last year, while for Aug 2025 it was 13.63%, marking a year-over-year increase of 531200.0%. This contributed to the annual value of 12.84% for FY2024, which is 510500.0% up from last year.
  • Latest data reveals that Cryo Cell International reported EBITDA Margin of 24.29% as of Q3 2025, which was up 70600.0% from 18.83% recorded in Q2 2025.
  • Cryo Cell International's EBITDA Margin's 5-year high stood at 27.69% during Q2 2021, with a 5-year trough of 205.37% in Q4 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 15.65% (2022), whereas its average is 2.81%.
  • In the last 5 years, Cryo Cell International's EBITDA Margin plummeted by -2105900bps in 2023 and then surged by 2038400bps in 2024.
  • Over the past 5 years, Cryo Cell International's EBITDA Margin (Quarter) stood at 11.05% in 2021, then surged by 147bps to 5.22% in 2022, then plummeted by -4033bps to 205.37% in 2023, then skyrocketed by 99bps to 1.52% in 2024, then soared by 1693bps to 24.29% in 2025.
  • Its last three reported values are 24.29% in Q3 2025, 18.83% for Q2 2025, and 13.25% during Q1 2025.